Catalyst
Slingshot members are tracking this event:
Phase 3 interim analysis data of Aurinia Pharmaceuticals' (AUPH) LUPKYNIS (Voclosporin) in Lupus Nephritis to be presented at the American College of Rheumatology (ACR) 2021 on November 3-9
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| AUPH | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 01, 2021
Occurred Source:
https://ir.auriniapharma.com/press-releases/detail/239/aurinia-announces-updated-interim-results-from-the-aurora-2
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Lupus Nephritis, Aurora-2
